Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
Want to see AU:PTX full AI Analyst Report?
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$54.68M
Enterprise ValueAU$46.46M
Total Cash (Recent Filing)AU$9.77M
Total Debt (Recent Filing)AU$495.89K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~44% revenue growth demonstrates improving commercial or collaborative traction and greater validation of the company’s activities. Over 2-6 months this supports continued investor and partner interest and underpins scaling of R&D investment and program advancement.
Balance Sheet ConservatismVery low leverage reduces refinancing and interest-rate risk, preserving strategic optionality. For a cash-burning clinical-stage biotech, minimal debt improves resilience to market volatility and extends flexibility to pursue partnerships or staged financings over the medium term.
Diversified Clinical PipelineMultiple therapeutic approaches (small molecule CXCR4 inhibitor plus allogeneic CAR‑T and TCR cell therapies) provide program optionality and de‑risking across modalities. This structural diversity increases partner appeal and multiple long‑term value creation pathways if trials progress.
Bears Say
Negative Free Cash FlowConsistent negative operating and free cash flow, with FCF worsening ~25% in 2025, signals a persistent cash burn profile. Over months this elevates reliance on external capital, increases dilution risk from financing, and can constrain development timing absent partnerships.
Structural LossesPersistent negative operating profit and net income indicate the company has not reached operating leverage. This structural unprofitability suggests margins are not yet sustainable and continued R&D spend will be required, pressuring capital needs and long‑term self‑funding ability.
Eroding Equity BaseDeclining equity and assets alongside negative ROE point to value dilution from ongoing losses. Over 2-6 months this weakens the capital base, reduces financial flexibility for large trials, and increases probability of dilutive financings or unfavorable partnership terms.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$54.68M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 135 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.353%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-62.49%
Trailing 12-Months
Asset Growth
11.46%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---